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Knockout of the epilepsy gene 
Depdc5 in mice causes severe 
embryonic dysmorphology with 
hyperactivity of mTORC1 signalling
James Hughes1,2, Ruby Dawson1,2, Melinda Tea3, Dale McAninch1,2, Sandra Piltz1,2, 
Dominique Jackson1,2, Laura Stewart1,2, Michael G. Ricos4, Leanne M. Dibbens4, Natasha L. 
Harvey3 & Paul Thomas1,2
DEPDC5 mutations have recently been shown to cause epilepsy in humans. Evidence from in vitro 
studies has implicated DEPDC5 as a negative regulator of mTORC1 during amino acid insufficiency 
as part of the GATOR1 complex. To investigate the role of DEPDC5 in vivo we generated a null mouse 
model using targeted CRISPR mutagenesis. Depdc5 homozygotes display severe phenotypic defects 
between 12.5-15.5 dpc, including hypotrophy, anaemia, oedema, and cranial dysmorphology as well 
as blood and lymphatic vascular defects. mTORC1 hyperactivity was observed in the brain of knockout 
embryos and in fibroblasts and neurospheres isolated from knockout embryos and cultured in nutrient 
deprived conditions. Heterozygous mice appeared to be normal and we found no evidence of increased 
susceptibility to seizures or tumorigenesis. Together, these data support mTORC1 hyperactivation as 
the likely pathogenic mechanism that underpins DEPDC5 loss of function in humans and highlights the 
potential utility of mTORC1 inhibitors in the treatment of DEPDC5-associated epilepsy.
Epilepsy is a collection of neurological disorders characterised by unprovoked seizures. Focal epilepsy is the most 
common type of epilepsy and is caused by a range of genetic and environmental factors. In focal epilepsies sei-
zures originate from a specific region of the brain as opposed to the generalised epilepsies where seizures originate 
from both hemispheres of the brain simultaneously. In 2013 we demonstrated that heterozygous DEPDC5 muta-
tions cause autosomal dominant focal epilepsies with variable expressivity and incomplete penetrance1. Atypical 
for genetic epilepsies, the locus of seizure origin is variable, even among affected members of the same family, 
and can include frontal, temporal, fronto-temporal, parietal and occipital regions of the human cortex. Since our 
initial observations were published, DEPDC5 mutations have emerged as a major cause of inherited focal epilepsy, 
with mutations also reported in cases of autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), familial 
temporal lobe epilepsy (FTLE), benign epilepsy with centrotemporal spikes (BECTS) and other small families 
and individuals with focal epilepsy2,3. A number of DEPDC5 mutations are frame shift or nonsense changes, 
indicating that they are likely to cause loss of function. Together these studies identify DEPDC5 as an important 
new genetic cause of focal epilepsy.
DEPDC5 encodes a 1604 amino acid protein that, with NPRL2 and NPRL3, forms the GTPase-activating-protein 
(GAP) Activity TOward Rags (GATOR1) complex 14. Interestingly, we have shown that mutations of NPRL2 
and NPRL3 also cause focal epilepsy4,5. GATOR1 inhibits mTORC1 when amino acids are in short supply by 
functioning as a GTPase-activating protein (GAP) for the Rag subfamily of small GTPases that normally facilitate 
mTORC1 translocation to its active site at the lysosomal membrane. The importance of the GATOR1 complex 
in amino acid sensing by mTORC1 is highlighted by its exquisite conservation from yeast to humans where the 
analogous yeast protein complex SEACIT is composed of Npr2p, Npr3p and Iml1p6.
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Mutations in GATOR1 genes give rise to patient phenotypes that overlap with Tuberous Sclerosis Complex 
(TSC), caused by mutations in TSC1 and TSC2. These genes encode proteins that form the tuberous sclero-
sis complex that also acts to negatively regulate mTORC1 signalling. While GATOR1 mediates repression of 
mTORC1 during nutrient starvation conditions, the TSC protein complex inhibits mTORC1 activity during lim-
ited growth factor availability7,8. Mutations in GATOR1 complex genes and TSC genes are both associated with 
epilepsy, brain malformations, autistic features and intellectual disability. It is not yet clear how the pathobiologi-
cal mechanisms leading to these phenotypes are linked.
To further investigate the function of DEPDC5 in vivo, we generated mice with loss of function alleles using 
CRISPR/Cas9 mutagenesis. We found that Depdc5 null mice died during embryogenesis, exhibiting retarded 
growth, anaemia, eye, liver, cranial and vascular defects. mTORC1 hyperactivation was detected in embryonic 
brain lysates and nutrient starved neurospheres and MEFs. These data indicate that mTORC1 hyperactivation is 
a likely pathogenic mechanism that results from DEPDC5 loss of function and points to the potential utility of 
mTORC1 inhibitors in the treatment of patients with DEPDC5 mutations.
Results
Generation of Depdc5 frameshift mutant mice using CRIPSR/Cas9 genome editing. To generate 
Depdc5 mutant mice we used TALEN and CRISPR/Cas9 genome editing technologies to induce double stranded 
breaks in exon 2 of Depdc5, with a view to creating frameshift mutations early in the open reading frame to dis-
rupt protein function. Mouse zygotes were injected with either mRNA for a pair of TALENs or Cas9 mRNA and 
gRNA, and transferred to psuedopregnant recipients for development to term. Two separate CRISPR gRNAs 
(C1 and C2) and one TALEN pair (T1) were used. Twelve founder mice carrying a total of 18 mutant alleles 
were generated (Fig. 1a). Interestingly, founders from TALEN injections did not contain any WT alleles, while 
both CRISPR guides resulted in founders with a mixture of WT and mutant alleles, suggesting that the rate of 
mutagenesis was higher for the TALEN pair in this experiment. Many mosaic founders were generated from both 
CRISPR and TALEN injections, supporting observations previously reported of persistent endonuclease activity 
into the two cell stage and perhaps later9–11 Upon analysis of founder genotypes it was striking that all animals 
contained at least one WT allele or a small in frame deletion typically of 3 base pairs. The overrepresentation of 
these likely functional in frame deletion alleles combined with the high mutation frequency observed by us and 
others9,12,13 suggested that animals with frameshift mutations on both alleles did not survive to weaning.
Eight frameshift alleles were generated of which six were transmitted through the germline (Fig. 1a and 
Supplementary Fig. S1a). A 22 base pair deletion (c77_99del/L23fsX65) derived from CRISPR Founder 1 (Fig. 1a, 
Supplementary Fig. S1a) was selected for further analysis due to ease of genotyping (Supplementary Fig. S1b) and 
is referred to hereafter as frameshift (FS). The intercross of FS heterozygotes failed to generate Depdc5FS/FS animals 
at weaning, further supporting the occurrence of FS homozygous embryonic lethality (Table 1, p < 0.0001). We 
anticipated that the frameshift in exon 2 adjacent to an intron/exon boundary may result in lower transcript levels 
due to nonsense-mediated decay, however we could detect no difference in transcript level between Depdc5+/+ 
and Depdc5FS/FS tissue (Fig. 1b). Using Depdc5FS/FS and Depdc5+/+ protein lysate we were unable to identify an 
antibody specific for DEPDC5, including a previously published1 antibody (D19 rabbit polyclonal antibody 
(Santa Cruz Biotechnology, sc-86116), we therefore confirmed the absence of DEPDC5 protein in Depdc5FS/FS 
animals using the mass spectrometry technique of parallel reaction monitoring (PRM). PRM is a highly sen-
sitive form of targeted mass spectrometry that allows the relative quantification of peptides. Figure 1c shows a 
representation of the relative quantitation of a transition for peptide 195AVNGFLADLFTK206 in comparison to 
the spectral library control. We noted some variability in the enrichment of y- and b-ions that we speculate is due 
to the low abundance of the peptide. Nevertheless these differences in enrichments are within acceptable toler-
ance. In addition an independent peptide (1238TFIYGFYFY1247) was detected by Selection Ion Monitoring (SIM) 
nano-LC-ESI-MS/MS in Depcd5+/+ lysate but not in Depdc5FS/FS lysate (Supplementary Fig. S2). Both peptides are 
downstream of the CRISPR target site in exon 2 and are encoded by exons 10–11 and 37 respectively, which are 
collectively present in all annotated mouse transcripts. Given the absence of these DEPDC5 peptides we conclude 
that FS constitutes a null allele.
To further investigate the timing of phenotypic onset in FS mice, we harvested embryos from heterozygous 
crosses at various stages of gestation. Only viable embryos with a discernible heartbeat were included. Depdc5FS/
FS embryos at 9.5dpc were macroscopically normal, while from 10.5-15.5 dpc displayed a range of developmental 
abnormalities including reduced size, micropthalmia/anopthalmia and hepatic hypoplasia. At 10.5 dpc the most 
penetrant phenotypes in Depdc5FS/FS embryos were reduced size (67%, Table 2) and micropthalmia/anopthalmia 
(44%, Table 2). Micropthalmia/anopthalmia and hepatic hypertrophy were highly penetrant by day 13.5dpc and 
at 14.5 dpc the majority of Depdc5FS/FS embryos displayed overt cranial dysmorphology (88%, Fig. 2 and Table 2). 
We noted that the severity of abnormalities was also variable within each time point and present examples repre-
sentative of each end of the spectrum for completeness (Fig. 2). The onset of severe phenotypes at midgestation 
indicates that DEPDC5 has an essential role during embryogenesis. This finding is consistent with our recently 
published expression data showing that Depdc5 transcript is expressed throughout mouse development with a 
modest peak at 12.5dpc5. Depdc5FS/FS embryos appear to be underrepresented when 12.5–17.5dpc embryo num-
bers were pooled (Table 3, Chi-square test, p = 0.051), suggesting variable lethality across this period of develop-
ment rather than one single day which is likely due to the variability seen in severity of phenotypes.
CRISPR mutagenesis is known to induce off target mutations at a low frequency in a sequence specific manner 
dictated by the gRNA sequence14,15. To confirm that the observed embryonic lethality was due to mutation of 
Depdc5 and not an off-target event, we generated an independent mutant line using an alternate strategy in which 
two gRNAs were directed against intronic sequence flanking exon 2 (Fig. 3a). Transmitting founders containing 
the intended frameshifting deletion of exon 2 (del) were identified. Morphological and histological analysis of 
del/del embryos at 13.5 and 14.5 dpc revealed identical abnormalities to Depdc5FS/FS embryos including severe 
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cranial dysmorphology, hepatic hypoplasia, reduced overall size and micropthalmia/anopthalmia and oedema 
(Fig. 3b–m). Taken together, these data confirm that the observed developmental defects result from Depdc5 loss 
of function.
Oedema in Depdc5 mutants is associated with defects in cardiovascular development. At 14.5 
dpc Depdc5FS/FS embryos were observed with oedema around the dorsal cranium, trunk and heart as well as 
discrete haemorrhagic blood pools in the skin (Figs 2b and 3). As these phenotypes are often associated with 
blood and lymphatic vascular development, we reasoned that such developmental defects could contribute to the 
embryonic lethality in mutant embryos. To further investigate this phenotype, we performed morphological and 
morphometric analysis of mutant tissue derived from viable embryos immunostained for markers of the blood 
(CD31) and lymphatic (PROX1, LYVE-1) vasculature. Analysis of yolk sacs from 14.5 dpc Depdc5FS/FS embryos 
revealed tortuous blood vessels. The skin of 14.5 dpc Depdc5FS/FS embryos exhibited aberrant blood vascular 
patterning, reduced lymphatic vessel branching and increased lymphatic vessel diameter (Fig. 4a–c). The jugular 
Figure 1. Generation of Depdc5 null mice. (a) Exon 2 of mouse Depdc5 was targeted with two separate 
CRISPR gRNAs or a pair of TALENs shown in bold (PAM shown in red, TALEN spacer shown in pink). 
(Frameshift Founder allele (FS) is depicted with deleted bases represented by dashes.) Founder alleles are 
depicted with deleted bases represented by dashes and inserted bases shown in green. (b) Depdc5 expression 
was measured from cDNA generated from 3 Depdc5+/+ and 3 Depdc5FS/FS 12.5 dpc brain RNA preparations 
and is expressed relative to beta actin expression. Two way comparisons were performed using unpaired 
two tailed Student’s t-tests, error bars represent SEM, n = 3. (c) Relative quantification of a DEPDC5 peptide 
195AVNGFLADLFTK206 was performed using PRM on head lysate from one Depdc5FS/FS 12.5dpc embryo and 
one Depdc5+/+ 12.5dpc embryo. Each colour represents the abundance of y- and b-ions of the protein of interest 
in comparison to the spectral library. dotp = dot product.
+/+ FS/+ FS/FS
Observed 37 57 0****
Expected 23.5 47 23.5
Table 1. Chi squared test for postnatal offspring from Depdc5FS/+ x Depdc5FS/+ cross, (p < 0.0001).
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lymph sacs of 14.5 dpc Depdc5FS/FS embryos were also enlarged (data not shown). Histological examination of 
15.5 dpc Depdc5FS/FS embryos confirmed the oedema observed by gross examination and revealed ventral septal 
dysplasia in the heart (Fig. 4d–f). These data reveal that Depdc5 is required both for cardiac development and for 
blood and lymphatic vascular development and suggest that abnormalities of the cardiovascular system may be 
the primary cause of Depdc5FS/FS embryonic lethality.
Abnormal mTORC1 signalling in Depdc5 mutants. Published in vitro studies indicate that DEPDC5 
functions as a negative regulator of mTORC14. To investigate the impact of Depdc5 loss-of-function on mTORC1 
signalling in vivo, we performed Western blot analysis of 13.5 dpc embryonic brain, a tissue that expresses Depdc5 
and is severely affected by mutation of DEPDC5 in patients. All embryos were viable at the time of collection. 
Markers of mTORC1 activity (Phosphorylated-S6-Ribosomal-protein (p-S6-S235/236 and p-S6-S240/244) and 
Phosphorylated-Ribosomal-protein-S6-kinase-beta-1 (p-p70S6k-T389) were significantly elevated in Depdc5FS/FS 
samples, but not Depdc5FS/+ samples, compared to Depdc5+/+ controls (Fig. 5, full length blots are shown in 
Supplementary Fig. S3). We noted however that the level of hyperactivation was variable. This variability did 
not correlate with morphological severity but given that 13.5 dpc Depdc5FS/FS embryos often exhibit profound 
developmental abnormalities (Fig. 2), we speculated that the direct effect of DEPDC5 loss of function could be 
masked in some samples due to secondary defects relating to embryo malformation and cell death. To address 
this we repeated our analysis on whole 9.5 dpc embryos, where gross morphological differences are not evident 
(data not shown). mTORC1 hyperactivation was also observed in Depdc5FS/FS embryos at this stage with subtle 
upregulation of p-S6-S235/236 and more pronounced upregulation of p-p70S6k-T389 (Supplementary Fig. S4, 
full length blots are shown in Supplementary Fig. S5), suggesting that the increased mTORC1 activation is due to 
the loss of DEPDC5 function.
To assess the responsiveness of Depdc5 null cells to amino acid starvation, we generated mouse embryonic 
fibroblasts (MEFs) and neurospheres from Depdc5FS/FS, Depdc5FS/+ and Depdc5+/+ animals and assessed mTORC1 
activity as described above. Under basal, nutrient replete, conditions we did not detect any difference in mTORC1 
downstream markers (p-S6-240/244, p-S6-240/244, p-p70-T389) in either MEFs or neuroprogenitors. However, 
when starved of amino acids and serum for 1 hour we observed increased mTORC1 signalling, as indicated by 
elevated levels of p-S6-240/244 in Depdc5FS/FS cells but not Depdc5FS/+ or Depdc5+/+ cells (Fig. 6a–d, full length 
blots are shown in Supplementary Figures S6–7). The direct involvement of mTORC1 was confirmed by inclusion 
of rapamycin, an mTORC1 inhibitor, which supressed the mTORC1 hyperactivity in Depdc5FS/FS cells (Fig. 6b,d). 
Together this data establishes that mTORC1 hyperactivation is observed in Depdc5FS/FS tissues both in vivo and 
in vitro and is consistent with the described role of DEPDC5 as an inhibitor of mTORC1 under low amino acid 
conditions4.
To further explore the impact of DEPDC5 mutation on mTORC1 signalling, we assessed levels of 
phosphorylated-AKT (p-AKT-S473). This upstream component of the mTORC1 pathway is stimulated in 
response to insulin signalling and can also receive feedback inhibition from p-S6 in response to chronic mTORC1 
hyperactivation16. Embryonic Depdc5FS/FS lysates showed significant downregulation of p-AKT-S473 consistent 
with feedback inhibition downstream of mTORC1 hyperactivation (Fig. 5). Interestingly, p-AKT-S473 downreg-
ulation was more consistent than mTORC1 downstream marker upregulation, such that even those Depdc5FS/FS 
lysates that did not exhibit pS6 upregulation still showed at least modest p-AKT downregulation (Supplementary 
Fig. S4). Similarly, in MEF and neurosphere culture, p-AKT-S473 and p-AKT-T308 downregulation was observed 
under nutrient replete conditions despite no apparent p-S6 upregulation (Fig. 6a,c).
Seizure and tumour susceptibility in Depdc5FS/+ mice. Depdc5FS/+ mice, which may best reflect 
patients heterozygous for a DEPDC5 mutation, exhibited normal growth and fertility (Fig. 7a). Given that 
humans with heterozygous mutations often develop epilepsy, we assessed the propensity of Depdc5FS/+ mice to 
exhibit spontaneous seizures under normal conditions and through the administration of the proconvulsant 
Pentylenetetrazol (PTZ)17. No overt spontaneous seizures were detected during 30 minute daily observations of 8 
female and 8 male heterozygous mice from weaning to 12 weeks under standard husbandry conditions. Nocturnal 
Phenotype 10.5dpc 12.5dpc 13.5dpc 14.5dpc
Reduced embryonic size
FS/FS 6/9 = 67% 3/6 = 50% 3/4 = 75% 3/8 = 38%
FS/+ 4/7 = 23% 0/16 = 0% 0/15 = 0% 2/29 = 7%
+/+ 0/4 = 0% 0/9 = 0% 0/9 = 0% 1/9 = 11%
Micropthalmia/anopthalmia
FS/FS 4/9 = 44% 5/6 = 83% 4/4 = 100% 8/8 = 100%
FS/+ 0/17 = 0% 0/16 = 0% 1/15 = 7% 2/29 = 7%
+/+ 0/4 = 0% 0/9 = 0% 0/9 = 0% 0/9 = 0%
Hepatic hypoplasia
FS/FS 1/9 = 11% 3/6 = 50% 4/4 = 100% 5/8 = 63%
FS/+ 0/17 = 0% 0/16 = 0% 0/15 = 0% 2/29 = 7%
+/+ 0/4 = 0% 0/9 = 0% 0/9 = 0% 0/9 = 0%
Cranial dysmorphology
FS/FS 0/9 = 0% 0/6 = 0% 1/4 = 25% 7/8 = 88%
FS/+ 0/17 = 0% 0/16 = 0% 0/15 = 0% 0/29 = 0%
+/+ 0/4 = 0% 0/9 = 0% 0/9 = 0% 0/9 = 0%
Table 2. Phenotype frequencies of Depdc5FS/+ and Depdc5FS/FS embryos.
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observation (when mice are most active) using Infrared (IR) recordings also failed to reveal overt spontaneous 
seizures in a cohort of 8 Depdc5FS/+ and 6 Depdc5+/+ mice. No significant difference in the PTZ-induced latency 
to tonic-clonic seizure was detected between a cohort of 4-6 month old 9 Depdc5+/+ and 14 Depdc5FS/+male 
mice (Fig. 7b). To investigate whether Depdc5 heterozygous mice exhibit pathological features associated with 
some DEPDC5 mutations in humans or other mTORC1 related pathologies such as giant or balloon cells18–22, 
we examined adult brains for cortical malformations and mTORC1 hyperactivation. Large p-S6-S240/244 bright 
Figure 2. Gross anatomy of midgestational embryos. (a) Representative embryos for each genotype at 12.5, 13.5 
and 14.5 dpc. Total numbers observed were; FS/FS, 12.5dpc = 6, 13.5dpc = 4, 14.5dpc = 8, FS/+, 12.5dpc = 16, 
13.5dpc = 15, 14.5dpc = 29, +/+, 12.5dpc = 9, 13.5dpc = 9, 14.5dpc = 9. The phenotypic variability of 
Depdc5FS/FS embryos is represented with a mild and severe example at each time point. (b) Examples of cranial 
dysmorphology at 13.5, 14.5 and 15.5 dpc. Oedema (arrow head) and haemorrhaging (asterisk) is shown.
+/+ FS/+ FS/FS
Observed 34 81 25
Expected 35 70 35
Table 3. Numbers each genotype of viable embryos collected between 12.5–17.5dpc. Chi squared test for viable 
12.5–17.5dpc embryos from Depdc5FS/+ x Depdc5FS/+ cross, (p = 0.051).
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cells have been reported in Depdc5 heterozygous rat brains23. Nissl-stained cells in layer V of the cortex were no 
larger in heterozygotes in comparison to wild type mice and histological analysis revealed no evidence of cortical 
malformations (Fig. 7c). Quantitative immunoanalysis for the mTORC1 hyperactivation marker p-S6-S240/244 
in the cortex also did not reveal any significant difference between Depdc5FS/+ and Depdc5+/+ mice (Fig. 7d). 
Given that other mice with mTORC1 repressor gene knockouts, such as TSC1 and TSC2, show these pheno-
types at comparable embryonic stages, we extended our analysis to older animals, where TSC heterozygotes show 
increased tumour incidence in the kidney and at other sites24,25. This would also be consistent with the observed 
role of the GATOR1 complex protein, NPRL2, as a tumour suppressor26,27. To investigate this we performed a 
phenotypic screen on two 12 month old and two 18 month old Depdc5FS/+ mice but did not observe any unusual 
tissue pathology upon histological examination of 21 tissues and organs (data not shown).
Figure 3. Independent Depdc5 null mice phenocopy Depdc5FS/FS mice. (a) Two independent gRNA directed 
to intronic sequence flanking exon 2 (black arrows) lead to the deletion of exon 2 (del). PCR primers external 
to the deletion (green arrows) generate a 500 bp band after deletion. (*Note that amplification of the expected 
2500 bp WT allele fails due to short extension time). PCR with primers internal to the deletion (red arrows), 
give a 650 bp band in WT allele only. Gross anatomy (b–d,h–j) and corresponding H&E (e–g, k–m) showing the 
phenotyope of del/del embryos.
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Discussion
Heterozygous mutation of DEPDC5 is emerging as a relatively frequent cause of familial focal epilepsy. Focal 
epilepsy is the most common form of epilepsy in humans. In vitro functional studies indicate that DEPDC5 is an 
inhibitor of mTORC1 signalling, suggesting that DEPDC5-associated epilepsy may result from aberrant mTORC1 
signalling, as is the case in tuberous sclerosis patients who often have epilepsy. To investigate the phenotypic 
consequences of Depdc5 mutation in vivo, we generated Depdc5 mutant mice using CRISPR/Cas9 and TALEN 
mutagenesis. Consistent with other studies utilizing these technologies to generate animal models, mutations 
were readily generated, highlighting the efficacy of zygotic genome modification for the generation of mouse 
models9,12,28. Depdc5FS/FS animals die at mid to late gestation, with a range of phenotypes including cranial dys-
morphology, general hypoplasia, micropthalmia/anopthalmia, oedema and haemorrhage. These phenotypes are 
also present in null embryos for the other GATOR1 complex members (Nprl2 and Nprl3) as well as TSC1 and 
TSC2 and Depdc5 null rats23,29–32, implicating mTORC1 hyperactivation in the observed lethality. We observed 
hyperactivation of mTORC1 in Depdc5FS/FS embryos at midgestation and demonstrated that Depdc5FS/FS mutant 
MEFs and neurospheres respond abnormally to nutrient starvation by retaining aberrantly high mTORC1 activ-
ity. Preliminary experiments were conducted attempting to rescue these embryonic phenotypes with the mTOR 
inhibitor rapamycin but were not conclusive and therefore further experimentation will be required to address 
this point. Together, our data demonstrate that DEPDC5 is essential for embryonic development and strongly 
suggest that aberrant mTORC1 activity is central to the mutant phenotype.
The phenotype of Depdc5FS/FS embryos was variable, particularly with respect to cranial development. Some 
embryos were only mildly affected with no overt loss of tissue organisation while others had severe cranial 
atrophy with unrecognisable tissue organisation, including a loss of lateral ventricles, eyes and jaw structures, 
Figure 4. Depdc5FS/FS embryos exhibit defects in blood and lymphatic vascular patterning. (a) Yolk sacs of 
14.5 dpc wild-type and Depdc5FS/FS embryos stained with CD31 (green) and LYVE-1 (cyan) revealed tortuous 
blood vessels in Depdc5FS/FS embryos. Skin of Depdc5FS/FS embryos exhibit reduced blood vessel density. 
Dermal lymphatic vessels (Prox1-positive, red) of 14.5 dpc Depdc5FS/FS embryos were significantly larger in 
calibre (****p < 0.0001) (a,b) and less branched (*p = 0.04953) (a, c) than wild-type counterparts. Two way 
comparisons were performed using Mann Whitney U test, error bars represent SEM, n = 3, FOV = field of view. 
White scale bars represent 100μm. (d) Gross anatomy of 15.5dpc embryos showing the plane of sectioning for 
e and f. Hematoxylin and Eosin stained sections (e and f) showing oedema (e, asterisk) and ventricular septal 
defect in Depdc5FS/FS embryos (f, arrow).
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while retaining more normal trunk structures. We speculate that this variability may be secondary to an earlier 
embryonic defect that may represent the primary cause of lethality. Although mTORC1 signalling is likely to be 
exquisitely regulated in all tissues, a good candidate for cause of death in Depdc5FS/FS embryos is defective cardi-
ovascular development. Quantitative analysis of the developing blood vasculature and lymphatic vasculature in 
Depdc5 null embryos revealed significant abnormities that likely underpinned the oedema and haemorrhaging 
that were observed. Notably, similar oedema, haemorrhaging and embryonic lethality have been reported in 
embryos with specific deletion of TSC in the developing vasculature33. Thus it appears likely that defective cardi-
ovascular development is a major contributor to the lethality of Depdc5FS/FS embryos.
DEPDC5 and TSC respond to different inputs into the mTORC1 pathway; amino acids and growth factors, 
respectively. We might therefore expect the phenotype of Depdc5 and TSC null mice to reflect the abundance of 
these inputs during embryogenesis, such that defects should only be seen at times or in tissues where these inputs 
are limiting. The striking similarity of the Depdc5 and TSC mutant phenotypes therefore suggests that both sets 
of stimuli are limiting during embryogenesis, which constitutes a period of very rapid cell growth and prolif-
eration. The phenotypic similarity may also reflect a level of crosstalk between these two arms of the mTORC1 
pathway such that perturbation of one arm results in defective sensing by the other arm. In support of this idea, 
it has been reported that TSC is able to sense amino acid deprivation via mTORC1 recruitment to the lysosomal 
membrane34,35. In the absence of TSC, mTORC1 lingers longer at the lysosomal membrane in low amino acid 
conditions, causing aberrant activity. It is possible that a similar mechanism may allow DEPDC5 to sense TSC 
inputs and if so, in the absence of DEPDC5, TSC would have reduced ability to switch off mTORC1 during low 
growth factor input. Further investigations are required to address these possibilities.
Given that DEPDC5 is ubiquitously expressed and that mTORC1 signalling is thought to be required in every 
cell of the developing embryo and adult, it is intriguing that humans with heterozygous DEPDC5 mutations only 
develop an overt pathology within the CNS. This contrasts with TSC patients who exhibit lesions in multiple 
organs and display a diverse range of associated pathologies in addition to those that overlap DEPDC5-related 
phenotypes. Of note, many Depdc5FS/FS embryos displayed severe cranial defects (Fig. 2), with several embryos 
showing more dramatic loss of head than trunk tissue. It is not clear why Depdc5 loss of function in mice results 
in such severe cranial defects given its ubiquitous expression. It suggests that DEPDC5 and GATOR1 play more 
prominent role in brain development, which may help explain why epilepsy is the predominant phenotype 
reported in humans with DEPDC5 mutations.
Figure 5. mTORC1 signalling is upregulated in Depdc5FS/FS embryos. Three independent 13.5 dpc brain lysates 
from each genotype were used. Densitometric quantitation was performed and analysed with unpaired two-
tailed Student’s t-tests, error bars represent SEM, n = 3, *p < 0.05, n.s. = not significant. Separate blots were used 
for each antibody using the same experimental samples and were processed in parallel. The images shown are 
cropped. Full-length blots and original images are shown in Supplementary Fig. S3.
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In addition to mTORC1 deregulation, we detected consistent AKT hypophosphorylation in Depdc5FS/FS  
tissues. The most parsimonious explanation for this finding is that it occurs via a negative feedback from 
phosphorylated S6 kinase to AKT. This well- established negative feedback loop has been reported to limit 
mTORC1 hyperactivation in situations of constitutive mTORC1 stimulation such as chronic insulin exposure, 
excess nutrients or genetic ablation of TSC16. This provides an interesting point of difference between TSC and 
Depdc5 null mice, such that in Depdc5 null tissues this feedback may have some ability to counteract mTORC1 
Figure 6. mTORC1 pathway upregulation following nutrient starvation in Depdc5FS/FS MEFs and neural 
progenitors. Immortalised MEFs (a,b) and differentiated neurospheres (c,d) were starved of nutrients 
for 1 hour before being collected for immunoblotting (a,c) or immunocytochemistry with anti-phospho-
S6-S240/244 (b,d). Depdc5FS/FS MEFs fail to downregulate markers of mTORC1 activation after starvation (a,b). 
Specificity of p-S6-S240/244 downregulation in response to starvation is demonstrated by rapid upregulation 
following 10 minute return to nutrient replete basal media (nutrients 10 min). Rapamycin (20 nM) ablated all 
p-S6-S240/244 staining in both MEFs (b) and neural progenitors (d). Basal AKT activity is lower in Depdc5FS/FS  
MEFs and neuroprogenitors (starved minus lane Depdc5FS/FS vs Depdc5+/+, a,c). Separate blots were used for 
each antibody using the same experimental samples and were processed in parallel. The images shown are 
cropped. Full-length blots or original images are shown in Supplementary Figures S6–7.
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hyperactivation, while in TSC null tissues AKT will be unable to influence mTORC1 due to the absence of the 
intervening TSC complex. This may result in more limited mTORC1 hyperactivation in Depdc5FS/FS embryos than 
in TSC null animals. This difference in mTORC1 pathway regulation may also help explain the milder presenta-
tion of DEPDC5 related disorders relative to TSC associated disease18 (Fig. 8).
Recently published Depdc5 KO rats23 display many similarities with the mice reported here, including KO 
lethality, general growth retardation and mTORC1 hyperactivation, but important differences are also seen. Most 
notably, we saw no evidence of pathology in heterozygous mouse brains, while in rats, cortical lamination was 
Figure 7. Heterozygous mice appear healthy, do not have overt seizures, have normal levels of p-S6-S240/244 
in Depdc5FS/+ adult brains and do not show cortical abnormalities. Mouse weights measured weekly from 3-16 
weeks (a) were not different between Depdc5+/+ and Depdc5FS/+ for both sexes, error bars represent SD. (b) 
Latency to tonic clonic seizure following PTZ administration was not significantly different (p = 0.17) between 
9 Depdc5+/+ and 14 Depdc5FS/+ 4-6 month old male mice as determined using a Mantel-Cox test. No mice were 
seizure-free at the end of the assay. (c) Representative Nissl-stained 12-24 week old mouse cortical sections. 
Three independent Depdc5 mutant mouse strains were examined (Depdc5+/+ n = 3, Depdc5FS/+ n = 3). Left 
images have cortical layer V-VI boundary in black box which is enlarged in the right higher magnification 
images. Scale bars 250μm and 100μm respectively. Quantification of neuronal soma size in layer V of the 
cortex (n = 3 per genotype with 30 cells measured per animal). Two tailed Student’s t-test was used, error bars 
represent SEM. (d) 4–6 weeks old cortical brain slices were stained for p-S6-S240/244 (green) and NeuN (red) 
(n = 3, Depdc5+/+, n = 3, Depdc5FS/+, n = 3) White scale bar represents 50μm. Mean intensity of p-S6-S240/244 
bright cells per field of view was not significantly different (n.s. p = 0.9990) between Depdc5+/+ and Depdc5FS/+ 
brains. (Depdc5+/+, n = 3, Depdc5FS/+, n = 3, at least 30 cells measured per animal across 6 images). Student’s 
t-tests were used, error bars represent SEM.
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disrupted and enlarged balloon-like and cytomegalic neurons were observed throughout the cortex and particularly 
in layers IV-V. This preponderance of abnormally large neurons was a surprising finding given that other murine 
heterozygotes lacking mTORC1 regulators (such as TSC) have not reported anything similar24,25,29,36,37. Indeed, the 
potential differences in gene expression, epigenome, rates of somatic mutations or neurogenic rate between the two 
species can lead to distinct phenotypes, especially for neurological diseases38. Furthermore, possible differences 
in the GATOR1/mTOR pathway (Fig. 8) may cause differences in sensitivity to loss of mTOR inhibition which 
could also contribute to species-specific effects. Recently it has been shown that random mono-allelic expression of 
Depdc5 occurs in mouse brains39 which could also represent an important point of difference in rats versus mice. 
Generation and analysis of additional rat mTORopathy models, particularly those already modelled in mice, should 
help uncover the aetiology of species differences. In any event, the lack of seizures observed in both heterozygous 
mice and rats suggests that DEPDC5 haploinsufficiency per se is not sufficient to cause epilepsy.
Absence of heterozygous pathology in mice is consistent with TSC mutant mice in which adult heterozygotes 
also fail to replicate clinical features associated with the human disease. Of note a recent publication reported 
seizures in TSC1 heterozygous mice that were subjected to conscious EEG recordings and were between 9–18 
days old40. It will be interesting to perform similar further analyses on Depdc5 mice at similar ages to see whether 
developmentally restricted seizures are also present. Indeed, EEG could detect rare or subclinical seizures that 
may be missed in behavioural observations/monitoring. Tellingly, mice with targeted deletion of both copies of 
TSC1 or TSC2 in the brain or specific brain regions are able to replicate many hallmarks of the human disease 
including the presence of tubers, enlarged p-S6 bright neurons and seizures24,25,29,36,37,41–43. Together with findings 
of Loss of Heterozygosity (LOH) in some human tubers, these observations have been used to support a second 
hit model underlying pathogenesis44–46. A recent report describing a somatic “second hit” mutation in DEPDC5 
in an individual with focal epilepsy and cortical dysplasia suggests that GATOR1 and TSC-associated epilepsies 
may share this underlying genetic mechanism21. It will now be important to produce a mouse model with targeted 
deletion of Depdc5 in a discrete brain region to test this hypothesis.
In conclusion, we report that Depdc5 null mice die at midgestation with mTORC1 hyperactivation and AKT 
downregulation. Heterozygous animals appear normal at all stages examined. Together with the remarkable sim-
ilarity of Depdc5 and TSC null mouse phenotypes our findings support the hypothesis that mTORC1 deregulation 
is likely to underpin DEPDC5 related epilepsy and raises the possibility that mTORC1 inhibition may be a viable 
therapeutic option in patients with DEPDC5 mutations as is being investigated for TSC patients47 (reviewed in48).
Materials and Methods
Generation and genotyping of mutant mice. Gene editing reagents were designed and purchased from 
ToolGen (South Korea). A TALEN pair was designed to target exon 2 of Depdc5 (5′-TGATGAGCTAGTCGTGAACC-3′) 
(5′-TCACATCAAACTTGGAGACA-3′). Two independent CRISPR guides were designed adjacent to the TALEN 
spacer region targeting 5′-TGATGTGAGGAAATACTTT-3′and 5′-GTATTTCCTCACATCAAACT-3′. TALEN 
mRNA pairs (40 ng/μL each) or Cas9 mRNA (50 ng/μL) with crRNA (33 ng/μL) and tracRNA (67 ng/μL) were injected 
into C57BL/6 N zygotes, transferred to psuedopregnant recipients and allowed to develop to term. Founder pups were 
screened for indels by PCR amplification across the targeted region (F-5′-ATACCAACATGATGGGGTGCC-3′, 
R-5′-GATCAGCAGGGTGCCTACTTT-3′) followed by digestion with T7 endonuclease (NEB). PCR products from 
indel-carrying founders were Sanger sequenced to identify specific mutations.
Figure 8. Model of signalling disruptions in Depdc5FS/FS mice. (a) DEPDC5 inhibition of mTORC1 is overcome 
by the presence of amino acids, while TSC1 inhibition of mTORC1 is overcome by growth factor signalling 
including insulin. Negative feedback loops exist to limit mTORC1 stimulation in times of chronic insulin 
stimulation. (b) Genetic ablation of Depdc5 disrupts the GATOR1 complex and prevents the mTORC1 pathway 
from sensing amino acid levels. The consequent aberrant mTORC1 activity yields abnormally high phospho-S6 
and phospho-p70S6k levels that subsequently provide negative feedback to reduce the levels of phospho-AKT. 
We predict that this may promote inhibition of mTORC1 by TSC1/2 and establish a tension with mTORC1 
upregulation by DEPDC5 deletion.
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Routine genotyping was performed by polyacrylamide gel electrophoresis in which PCR products gener-
ated with the above primers spanning the target region were separated on 15% polyacrylamide TBA gels. 
Homoduplexes run at the expected sizes, while heteroduplexes had retarded electromobility.
All animal work was conducted following approval by The University of Adelaide Animal Ethics Committee 
(approval number S-2013-186) in accordance with the Australian code for the care and use of animals for scien-
tific purposes.
Histological analyses. Embryos for histological examination were fixed in 4% PFA, embedded in paraffin, 
cut at 6μm and stained with Mayer’s hematoxalin and Eosin using standard protocols. Nissl (C5042) staining was 
performed using standard protocols on perfused brains of three mice from three independent Depdc5 mutant 
mouse strains. All mouse lines targeted the same exon and generated a frameshift mutation (−22bp, −4bp as 
shown in Fig. 1 and −2 kb as shown in Fig. 3). Images were captured and analysed using Nikon Eclipse Ti micro-
scope and Nikon Digital Sight DS-Qi1 camera.
Real time PCR. RNA was extracted from 12.5 dpc brains by using Trizol (Thermo Fisher) and purified 
further on an RNeasy mini column (Qiagen). Reverse transcription was performed on 1 μg of RNA using a 
High Capacity RNA to cDNA synthesis kit (Life Technologies). Real time PCR was performed on a Step One 
Plus thermocycler (Life Technologies) using Fast Sybr green master mix (Life Technologies) according to 
manufacturer’s instructions on a two-step programme. Primers and product sizes were as follows; Depdc5 
(109 bp) F-5′-TGGGGACAAACCCCGTGCAG-3′ R-5′-CATGCGGTCTGAGCGGTGGC-3′, β-actin (89 bp) 
F-5′-CTGCCTGACGGCCAGG-3′ R-5′-GATTCCATACCCAAGAAGGAAGG-3′.
Immunofluorescence. For whole mount staining of tissues, yolk sacs or embryos were fixed overnight in 
4% paraformaldehyde at 4 °C. Following fixation, tissues were washed extensively in PBS and skin was dissected 
from the dorsal region of embryos. Yolk sacs and skin were blocked for 1 h at room temperature in 1% bovine 
serum albumin, 0.3% Triton-X in PBS, followed by incubation with primary antibodies diluted in blocking solu-
tion overnight at 4 °C. Yolk sacs were stained with rat anti-CD31 (BD Pharmingen, 553370, 1:500) and rab-
bit anti-mouse LYVE-1 (Angiobio, 1:1000). Skins were stained with rat anti-CD31 and goat anti-Prox1 (R&D 
Systems, AF2727, 1:250). Tissues were washed extensively in PBS containing 0.1% Triton X-100 (PBS-T), then 
were incubated overnight at 4 °C with Alexa Fluor-conjugated secondary antibodies (Molecular Probes, Life 
Technologies) diluted in blocking solution. The following day, tissues were washed extensively in PBS-T and 
mounted in DAPI Fluoromount G (ProSciTech). Tissues were imaged using confocal microscopy as previously 
described49 using a Zeiss LSM 700 confocal microscope (Zeiss Laboratories). Images were compiled using ZEN 
lite 2012 (black edition) version 8.1. Adult mice were perfused with 4% PFA/PBS, brains were removed, postfixed 
for a further 16 hours, cryoprotected in 30% sucrose, and embedded in OCT medium. Sections (12 μm) were 
prepared using a Leica CM1900 cryostat. Blocking in PBS/0.1% Triton X-100/10% horse serum was performed 
for 30 minutes, followed by overnight incubation at 4 °C in the same solution containing diluted primary anti-
body. Sections were washed 3 times for 10 minutes in PBS and incubated in diluted secondary antibody at 4 °C 
for 6 hours. After washing 3 times for 10 minutes each in PBS, slides were mounted in Prolong Gold Antifade 
plus DAPI (Molecular Probes, Invitrogen) and imaged using a Nikon Eclipse Ti microscope and Nikon Digital 
Sight DS-Qi1 camera. Antibodies and their corresponding dilutions were: rabbit anti phospho-S6 Ribosomal 
Protein (Ser235/236) (Cell Signalling, #2211, 1:1000), rabbit anti phospho-S6 Ribosomal Protein (Ser240/244) 
(Cell Signalling, #5364, 1:1000), mouse anti-NeuN (Millipore, #MAB377, 1:100).
Protein extraction and western blotting. Snap frozen embryos or brains for protein extraction were 
minced in extraction buffer (150 mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.1%SDS, 50 mM Tris-HCl pH 7.5) and 
incubated at 4 °C for 30 minutes. Lysates were separated on Invitrogen Bolt precast 4–12% polyacrylamide gels and 
transferred to PVDF membrane before blotting. Antibodies and their corresponding dilutions were: rabbit anti 
phospho-S6 Ribosomal Protein (Ser235/236) (Cell Signalling, #2211, 1:1000) rabbit anti phospho-S6 Ribosomal 
Protein (Ser240/244) (Cell Signalling, #5364, 1:1000), rabbit anti phospho-p70 S6 Kinase (Thr389) (Cell Signalling, 
#9234, 1:1000), rabbit anti phospho-AKT (Ser473) (Cell Signalling, #4060, 1:2000), rabbit anti phospho-AKT 
(Thr308) (Cell Signalling, #13038, 1:750), rabbit anti p70 S6 Kinase (Cell Signalling, #9202, 1:500), rabbit anti S6 
Ribosomal Protein (Cell Signalling, #2217, 1:750) and rabbit anti mTOR (Cell Signalling, #2983, 1:1000).
Detection of DEPDC5 using parallel reaction monitoring (PRM) and selected ion monitoring 
(SIM) nano-LC-ESI-MS/MS. Protein lysates from heads of one 12.5 dpc Depdc5FS/+ embryo and one 
12.5dpc Depdc5+/+ embryo were quantified using an EZQ protein assay (Life Technologies) and 2 µg of each 
sample was trypsin digested using the FASP method as previously described by50. LC-ESI-MS/MS was performed 
using an Ultimate 3000 nano-flow system (Dionex) coupled to an Impact II QTOF mass spectrometer (Bruker 
Daltonics) via an Advance CaptiveSpray source (Bruker Daltonics). 10 uL of each digested sample was loaded 
onto a trapping column (Acclaim PepMap100 C18, pore size 100 Å, particle size 3 µm, 75 µm × 2 cm length, 
Thermo Scientific) at 5 µL/min using 0.1% FA, 2% ACN in water for 10 min. Peptide separation was performed 
on a Acclaim PepMap RSLC column (C18, pore size 100 Å, particle size 2 µm, 75 µm × 50 cm length, Thermo 
Scientific) at 0.2 µL/min using a linear gradient of 5–45% ACN in 0.1% FA over 130 min.
PRM was performed on the QTOF using the following parameters for the peptide AVNGFLADLFTK; m/z 
648.3533, collision energy of 26, and an isolation width of 4. Data was analysed using the open source software 
Skyline where it was compared to a DEPD5 spectral library acquired PeptideAtlas (http://www.peptideatlas.org/
speclib/). The following Skyline settings were used; trypsin digestion, no missed trypsin cleavages, variable mod-
ifications of carbamidomethyl and oxidation, and mass error tolerance of 40 ppm.
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Selected ion monitoring (SIM) nano-LC-ESI-MS/MS was performed using an Ultimate 3000 RSLC system 
(Thermo-Fisher Scientific, Waltham, USA) coupled to an Impact HD™ QTOF mass spectrometer (Bruker 
Daltonics, Bremen, Germany) via an Advance CaptiveSpray source (Bruker Daltonics). SIM is highly sensi-
tive form of mass spectrometry as only peptides of interest are targeted for fragmentation and detection (based 
on their m/z) whilst all other peptides are excluded from data acquisition. 500 ng of the tryptic digests were 
pre-concentrated onto a C18 trapping column (Acclaim PepMap100 C18 75 μm × 20 mm, Thermo-Fisher 
Scientific) at a flow rate of 5 μL/min in 2% (v/v) ACN 0.1% (v/v) FA for 10 minutes. Peptide separation was per-
formed using a 75 μm ID C18 column (Acclaim PepMap100 C18 75 μm × 50 cm, Thermo-Fisher Scientific) at a 
flow rate of 0.2 μL/minutes using a linear gradient from 5 to 45% B (A: 5% (v/v) ACN 0.1% (v/v) FA, B: 80% (v/v) 
ACN 0.1% (v/v) FA) over 70 minutes, followed by a 20 minute wash with 90% B, and a 20 minute equilibration 
with 5% A. A proteotypic peptide from DEPDC5 was targeted in the SIM analysis; TFIYGFYFYK (m/z 674.83) 
at a mass width of 0.1 Da with a collision induced dissociation energy of 33. The acquired spectra were analysed 
using the MaxQuant software (version 1.5.2.8) with the Andromeda search engine. The standard Bruker QTOF 
settings were used with a mass error tolerance of 40 ppm and the digestion enzyme specified as trypsin. The 
peptide and protein false discovery rates (FDR) was set to 1%. The dot-product (dotp) is a calculation for the nor-
malized contrast angle, a comparison value between the peak areas (from the PRM acquisition) and the matching 
MS/MS peak intensities (from the spectral library).
Mouse Embryonic Fibroblast isolation and immortalisation. Mouse embryonic fibroblasts were 
isolated from eviscerated 13.5 dpc trunks. Following tryptic digestion, cells were cultured on standard tissue 
culture plastic in DMEM supplemented with 10% FCS, 1% glutamax and 1% penicillin/streptomycin. MEFs were 
immortalised by serial passage. For starvation experiments MEFs were cultured in DMEM lacking amino acids 
(US Biologicals, # D9800-13) and without serum supplementation. Rapamycin (Cayman Chemicals) was used at 
a final concentration of 20 nM.
Neurosphere growth and differentiation. Neurospheres were isolated from 13.5 dpc cortices. 
Cortices were stripped of meninges, minced with a scalpel blade and digested in papain (Worthington, 
#LK003178) supplemented with DNase (40 μg/mL, Worthington, #LS002139). Digestion was inhibited with 
a 1:1 mixture of BSA (Sigma) and ovomucoid (Worthington) in PBS and tissue triturated with fire polished 
glass pipettes. Single cells were cultured in neurosphere media (25% DMEM, 25% F12, 50% neurobasal, 2% 
B27, 10 ng/mL EGF, 20 ng/mL bFGF2). Subsequent passaging was performed with accutase (Sigma) by rinsing 
spheres in Ca/Mg free PBS, resuspending in accutase for 10 minutes and triturating with fire polished glass 
pipettes. Neurospheres were dissociated and differentiated for 3 days to a population of SOX3-positive neural 
progenitors for starvation experiments.
Whole animal phenotyping. Four 12–18 month old male and female mice were sent for whole animal 
phenotyping to the Australian Phenomics Network. Histological analysis of 21 tissues and organs was conducted 
by a veterinary pathologist.
Daily and nocturnal monitoring. Thirty minute daily observations were performed on 8 female and 8 
male heterozygous mice from weaning to 12 weeks under standard husbandry conditions. Nocturnal monitoring 
was performed by recording with an infrared camera mounted above a perspex covered cage in which mice had 
free access to food and hydration gel. Cohorts consisted of eight heterozygous (four male, four female) and six 
control wildtype mice (three male, three female), aged 16–20 weeks. Each mouse was recorded for 12 hours.
PTZ assay. Seizure susceptibility was measured by subcutaneous injection of pentylenetetrazole (PTZ) 
(120 mg/kg). 9 Depdc5+/+ and 14 Depdc5FS/+ 4–6 month old male mice were observed individually in clear cylin-
ders for drug-induced seizure phenotypes culminating in tonic-clonic seizure. Other measures of seizure suscep-
tibility including seizure duration and severity were not recorded due to ethical considerations.
Statistical Analysis. The Lymphatic Vessel Analysis Protocol (LVAP)51, Image J plug-in was used to analyse 
lymphatic vessel branch points and vessel diameter. One image per embryo was used to analyse lymphatic vessel 
branch point. Three embryos across two different litters were analysed for each genotype (n = 3 per genotype, 
p = 0.04953). Two way comparisons were performed using Mann Whitney U tests for both parameters. The LVAP 
was also used to analyse lymphatic vessel diameter as previously described51. Briefly, a grid was applied to each 
image, and the lymphatic vessel diameter was measured at the point at which the horizontal and vertical grid lines 
intersected. A minimum of 30 measurements were recorded per image, (n = 3 per genotype, p < 0.0001)
Densitometric quantification was performed on three biological replicates on a single Western blot using 
a Biorad Chemidoc with Image Lab software. Three independent embryo samples were run for each genotype 
and two way comparisons were performed using unpaired two tailed Student’s t-tests. PTZ survival plots were 
compared using a Mantel-Cox test. Observed and expected numbers of embryos or offspring with pooled FS/+ 
and +/+ compared to FS/FS using a Chi-square test. NIS software was used to measure mean intensity of PS6 
240/244 stained neurons by selecting and measuring the 5 brightest cells per field of view and subtracting a 
background non-stained measurement (n = 3 per genotype, 6 images taken per animal with at least 30 cells 
counted per animal). Mean intensity was compared using unpaired two-tailed Student’s t-test. NIS software 
was used to measure soma size in Nissl-stained sections (n = 3 of each genotype, 50 cells measured with the 
largest 30 used for statistical analysis (two-tailed Student’s t-test). All statistical tests were performed using 
GraphPad Prism 6 software.
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